HEB HEB

Hemispherx Biopharma Stock Price

1.80
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
1.80
Volume 0
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Hemispherx Biopharma Inc New HEB AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.80 19:00:00
Open Price Low Price High Price Close Price Prev Close
1.80 1.80
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.80 USD

Period:

Draw Mode:

Hemispherx Biopharma Inc New Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.40M 2.44M - $ 367.00k $ - -9.86 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
120.65k $ - - 876.73k -

more financials information »

Hemispherx Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HEB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years14.0828.601.699.911,044,396-12.28-87.22%

Hemispherx Biopharma Description

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.